Pfizer Inc.
IRA Drug Price Negotiation — Round 3 Expansion
4 Pfizer drugs added to Round 3: Eliquis (co-marketed), Ibrance, Prevnar 20, and Paxlovid. Combined revenue exposure: $14.2B. Therapeutic value framework could impose 45-65% price reductions, exceeding original 40-60% projections.
AI Accountability and Transparency Act
AI-driven drug discovery and clinical trial design tools subject to healthcare high-risk provisions. FDA AI/ML framework may create regulatory overlap. Compliance burden manageable given existing FDA oversight.
R&D Tax Credit Permanence and Expansion Act
Pfizer's $11.4B annual R&D spend immediately benefits from restored deduction — estimated $1.9B tax savings retroactive to 2022. Enhanced 25% credit increases ongoing annual benefit by $340M.
NIH Reauthorization and Cancer Research Acceleration Act
Public-private research partnership provisions enable expanded NIH-Pfizer collaboration on oncology and rare disease programs. ARPA-H permanence creates pathway for high-risk drug development funding. Clinical trial modernization reduces Pfizer's Phase II-III timelines.